Because food has not always been readily available, the human brain has evolved to signal us to eat when food is available. Today, this default hunger contributes to widespread obesity. Although a single weight-loss drug is unlikely to “cure” obesity, a mix of a drug approach, psychological approaches and exercise could be effective. (© 2009 Photo Researchers, Inc.)
Tuesday, October 27, 2009

Wired for Hunger: The Brain and Obesity

By: Marcelo O. Dietrich M.D. and Tamas L. Horvath D.V.M, Ph.D.

Because food is not always plentiful, humans have evolved to eat whenever it is available. Researchers are starting to tease out the brain circuits that elicit this “eat” message, a network that may contribute to today’s widespread obesity. Effective obesity treatment likely will involve combination of drugs, in addition to psychological approaches and exercise—not just a single pill. An accompanying story addresses what goes wrong in people with anorexia nervosa.

For most of human history, food was not readily available; storing energy helped ensure survival. Humans thus evolved to eat whenever food is at hand—a tendency that in the modern world may contribute to widespread obesity. Researchers are starting to determine the brain circuitry responsible for this default “eat” message. Marcelo Dietrich and Tamas Horvath tell the story of false starts and measured successes in obesity research. They propose that developing successful obesity therapy may require combining drug therapy with psychological or psychiatric approaches, as well as exercise. In the sidebar, they examine the opposite of obesity: anorexia nervosa.

In 1994, a scientific finding shot through the research world and then raced far beyond. It inspired wonder and, particularly among discouraged people struggling with severe weight problems, great hope. The report described how a molecule, leptin (from the Greek leptos, meaning “thin”), which is present in humans and other animals, powerfully influenced eating in laboratory experiments with obese mice.1 With good reason, experts speculated freely about defeating obesity—while giving appropriate cautions about the need for more research—and the discussion filled the airwaves and pages of newspapers and magazines for months. But then, just as quickly, leptin was gone. Further research failed to demonstrate a beneficial effect in people, and the “next big thing” was dethroned. People who had hoped leptin would be their salvation were disappointed and frustrated.

But the breakthrough and subsequent experiments with leptin did not leave scientists disappointed—far from it. They had turned an essential corner on the road to understanding the brain and obesity, and researchers have discovered much more in the 15 years since. In this article, we will explain what we now understand about one of the master controllers of this very intricate brain-body relationship. We also offer a surprise ending—of the good news–bad news sort.

Understanding Energy Balance

When thinking about obesity, it is important to remember that consuming food to store energy is fundamental for survival—and nature has done all it can to thwart interference with this mechanism. Much of evolutionary development has been about preserving and synchronizing opportunities to obtain and consume food to maintain a precise balance between food intake and energy expenditure (energy balance).

In the wild, sources of food were few and dispersed widely; early humans had to travel great distances to find food and safe places to rest. Because agriculture developed later on the evolutionary scale (by most estimates, only 10,000 years ago), this migratory behavior required high levels of daily activity. Additionally, because food was scarce, it was essential for us to develop a biological system to store energy. In humans, the largest depot of stored energy is our fat—specifically, the white adipose tissue. Thus, for most of human history, the struggle for life was about seeking, consuming and storing food, and our brains and bodies adapted to thrive in these environmental conditions.

In contrast, humans in modern societies can obtain food on demand and, in many instances, they have low activity levels (low energy expenditure) resulting in what is called positive energy balance—we consume more calories than we burn. This chronic, positive energy balance leads to obesity (accumulation of fat tissue) and its associated problems, including diabetes, cardiovascular disorders, cancers and neurodegenerative diseases. A striking development is that in the last few decades, adults have not been alone in their struggles with obesity. Children have become fat at an alarming rate, making childhood obesity a major health issue for most societies.2 We are seeing an epidemic of positive energy balance.

The Role of the Brain in Maintaining Energy Balance

Several brain nuclei—identifiable groups of neurons functioning together in specific brain areas—regulate the coordination of food intake and energy expenditure. Some of these nuclei are housed within the hypothalamus, a structure that lies just above the brain stem and helps control essential processes such as metabolism, sleep-wake states, body temperature, blood pressure, hunger and thirst and, through connections to other brain circuits, helps regulate brain activities. The hypothalamus was one of the first brain regions to evolve.

One nucleus that helps regulate energy balance is located in the most basal (lowest) part of the hypothalamus and has the form of an arc, giving it its name, the arcuate nucleus (ARC). Researchers have focused their attention on the ARC in recent decades because it has a singular role in energy balance and because it is located in one of the few areas in the brain that is not protected by the blood-brain barrier, the tightly meshed cell structure of blood vessel walls that keeps most blood-borne molecules from entering nearly all brain areas.

Within the ARC is the heart of what scientists believe is the main system for regulating food intake, the melanocortin hormone system. During a meal, various substances are released in the blood, enter the ARC and signal the melanocortin system to end the meal. To sense these substances, the system uses two side-by-side groups of specialized neurons with opposing actions. One neuronal group produces melanocyte-stimulating hormones (MSH) that suppress appetite, while the other neuronal group produces molecules that inhibit these hormones’ actions and stimulate appetite.

 MSH hormones signal the brain that no food is needed via a several-step process. The appetite-suppressing neuronal group produces a molecule called proopiomelanocortin (POMC). This molecule ultimately creates large peptides (the building blocks of proteins) that are then broken down by enzymes into small peptides including the appetite-suppressing MSH hormones. These  hormones bind to and activate melanocortin receptors located on brain cell surfaces that will signal the rest of the brain that food is not needed.

Two appetite-stimulating molecules, however, oppose the action of these MSH hormones. These two molecules, neuropeptide Y (NPY) and agouti-related protein (AgRP), are produced by neurons adjacent to the POMC cells. These molecules successfully compete against the MSH hormones to bind to the same melanocortin receptors on brain cells and inhibit their activity, so that the rest of the brain no longer receives the signal that food is unnecessary. The interaction between NPY/AgRP (appetite-stimulating) and POMC (appetite-inhibiting) neurons, therefore, regulates food intake.

Moreover, the brain has a redundant system for promoting the urge to eat. Appetite-stimulating neurons also produce the chemical neurotransmitter gamma-aminobutyric acid (GABA), which inhibits the POMC neurons from producing MSH hormones. During periods of negative energy balance, therefore, appetite-stimulating NPY/AgRP molecules inhibit the message that no more food is needed in two ways: They limit production of MSH and they prevent existing MSH from signaling.

This redundant system, then, promotes eating by (1) directly prompting food intake via the appetite-stimulating molecules NPY and AgRP and (2) sending signals that inhibit POMC neurons from suppressing appetite. Strikingly, even though the predominance of appetite-stimulating activity in this system is driven by negative energy balance— the need for food—its influence over POMC neurons seems to be the brain’s default system. In other words, the human brain has the default wiring: “I am hungry.”

This system had profound evolutionary consequences. The redundant mechanism to promote eating aided in survival when food was scarce, yet today when food is available at our discretion and the energy stores (fat tissue) are sufficient to maintain the energy needed for the body’s metabolism, the brain’s default wiring still signals us to keep eating. This mechanism, therefore, might be a key contributor to the current worldwide epidemic of obesity.

Enter Leptin and Visions of Treatment

 More than a century ago, British neurophysiologist Sir Charles S. Sherrington suggested that certain factors arising from the blood regulated food intake.3 Seven decades later, scientists discovered that a naturally obese mouse (named ob/ob because of its mutant genes) became leaner if it received some blood from a naturally lean mouse.4–6 These experiments provided convincing data that something about the blood was driving the physical characteristics of the ob/ob mice. Since then, growing evidence has shown that the tissues in the brain and the rest of the body communicate, almost certainly by the way of the bloodstream, to signal and to sense stimuli that regulate food intake.7

In 1994, Jeffrey Friedman and others at Rockefeller University discovered that ob/ob mice lacked leptin, a hormone produced by fat tissue. Researchers later found that leptin enters the brain and signals the ARC neurons to decrease food intake, thus inducing satiety.8, 9 Then, in 2004, innovative research revealed that leptin can induce a re-wiring of NPY/AgRP and POMC cells in the ARC in such a way that the network departs from its default signaling of hunger and adapts to a positive energy balance, thus decreasing appetite.10

Administering leptin to obese patients to decrease their appetites, however, proved ineffective. The leptin treatment cured only a few individuals with a rare, genetic type of obesity (due to mutations in the gene that produces leptin, as was the case with the ob/ob mice). Further investigation proved that, with the exception of patients with this rare genetic mutation, the brains of obese people somehow develop a resistance to leptin, and the cells in the brain stop sensing the levels of leptin in the blood.11 Thus, because the brains of the great majority of obese people cannot sense levels of leptin, using it to treat obesity is ineffective from the start.

Understanding the causes of leptin resistance in obese people, though, may help researchers identify new targets for treatment designed to restore their sensitivity to this hormone. Finding ways to heighten tissue sensitivity to hormone signals is difficult but not impossible, as diabetes management shows: People with type 2 diabetes are treated with compounds to increase their sensitivity to insulin. We hope for the development of a similar drug treatment for obese people, but, until we know what causes their resistance to leptin, investigation into such new compounds will remain in its infancy.

Researchers have found, in addition to leptin, several other hormones and molecules that regulate food intake by acting directly in the brain. For example, the gastrointestinal system has been a target of research because scientists believe it releases many hormones to signal a negative or positive energy balance. Investigators have taken a particular interest in the finding that the gut, mainly the stomach, produces the important appetite-stimulating molecule ghrelin, which also acts in the hypothalamus to prompt eating. Researchers found that ghrelin activates the NPY/AgRP appetite-stimulating neurons in response to negative energy balance (for example, when a person is fasting or following a low-calorie diet).12–14

Studies investigating how ghrelin affects the activity of NPY/AgRP neurons in the ARC have encouraged researchers by showing a cascade of events in these cells that ends by stimulating food intake.15 This sequence of events suggests several points of possible intervention for new therapies to treat energy balance disorders. First, ghrelin released by the gut enters the brain and stimulates a receptor on the NPY/AgRP cells that prompts secretion of growth hormone, thus increasing their appetite-stimulating activity. At the same time and related to this event, the mitochondrial machinery in the NPY/AgRP cells speeds up to deliver enough of the high-energy molecule adenosine triphosphate (ATP) for cell metabolism. The enhanced mitochondrial activity also increases the production of harmful oxygen molecules derived from mitochondrial respiration. These harmful molecules are free radicals that react with other molecules inside the cell and promote cell damage (for example, damage to the DNA). To protect the cell from such oxidative damage, the NPY/AgRP cells call on another mechanism to buffer these free radicals by activating the mitochondria’s uncoupling proteins. With appropriate buffering of free radicals by the uncoupling proteins, the NPY/AgRP cells can maintain high firing rates, thereby stimulating food intake.

Understanding this process may affect more than obesity research; it opens many lines of investigation to target cellular pathways to regulate energy balance—for example, by aiming at uncoupling proteins or the cells’ methods for buffering free radicals. In addition to suggesting an approach to solving eating problems, the possibility that free radicals play a role in modulating appetite and regulating energy homeostasis provides a promising avenue for the development of treatments for many diseases related to metabolism. Researchers can now test this promising theory with several newly developed compounds that act as antioxidants.

Moreover, scientists have identified several other molecules involved in regulating food intake. We won’t describe them, but they serve as a reminder of how intricately evolution built this regulatory network. For example, the gut produces several eating-related molecules in addition to ghrelin. Adipose tissue produces, in addition to leptin, immune system molecules with a role in diabetes and obesity. Lastly, classic regulatory hormones such as the glucocorticoids, produced by the adrenal glands and thyroid hormones, also control food intake.

The Feasibility of Treating Obesity with New Pharmacological Therapies

In the past two decades, researchers have worked hard to understand the biological abnormalities involved in obesity and to identify cellular pathways as possible targets for pharmaceutical treatments. The brevity of leptin’s shining moment dashed the hope that a single molecule could cure obese patients by counteracting their positive energy balance. This may be due to the different types of fuel utilization and overall metabolic consequences of the activity of NPY/AgRP versus that of POMC neurons. Fatty acids drive the firing of NPY/AgRP cells, while glucose drives the firing of POMC cells, showing that the former, which promote feelings of hunger and stimulate eating in response to negative energy balance, are a priority for survival.

Add this dominance—not to mention the default status—of the “get something to eat” component of the melanocortin system to the evolutionarily programmed rapid adaptability of brain circuits in response to the changing metabolic environment, and you can understand why it is a daunting and futile, if not counterproductive, task to attempt to develop a pill that will keep people from feeling hungry. Although a one-pill solution to obesity is unlikely, several avenues of research raise hope for new treatments for this widespread medical condition.

The first important step in managing obesity is to integrate disciplines. Based on the knowledge of the neurobiological basis of food intake, scientists could design a treatment using a mixture of compounds given at appropriate times. However, because of the influence of higher brain functions on the regulation of appetite—for example, the influence of the smell, taste and appearance of food on the stimulation of hunger—practitioners must also consider a psychological approach to treating obesity.

Indeed, we believe that obesity, like other disorders of energy metabolism (see “Anorexia Nervosa: a Mortal Clash between Reward and Hunger”), should also be treated as a psychological/psychiatric disorder. Additionally, because obesity involves not only elevated energy intake but also decreased energy expenditure, an exercise program is mandatory to its treatment. Finally, because obesity develops over many years, obese patients should expect a similar time scale to return to their ideal body weight after starting treatment.

This combination of treatment would take advantage of our new understanding of the brain’s role in obesity, going beyond the “silver bullet” visions that followed the discovery of leptin. As scientists continue to learn more about appetite stimulation and appetite suppression in the brain, as well as the hormones and other players that contribute to the process, we trust we will soon reach the goal of stemming the spread of obesity.

References

1. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, “Positional Cloning of the Mouse Obese Gene and Its Human Homologue,” Nature 372, no. 6505 (1994): 425–432.

2. A. M. Cali and S. Caprio, “Obesity in Children and Adolescents,” Journal of Clinical Endocrinological Metabolism 93(11 Suppl 1, 2008): S31–S36.

3. C. Sherrington, “Cutaneous Sensation,” in Textbook of Physiology, ed. E. A. Sharpey-Schaefer, 920–1001 (Edinburgh: Young J. Pentland, 1900).

4. D. L. Coleman and K. P. Hummel, “Effects of Parabiosis of Normal with Genetically Diabetic Mice,” American Journal of Physiology 217 (1969): 1298–1304.

5. D. L. Coleman, “Effects of Parabiosis of Obese with Diabetes and Normal Mice,” Diabetologia 9 (1973): 294–298.

6. D. L. Coleman, “Diabetes-Obesity Syndromes in Mice,” Diabetes 31 (1982): 1–6.

7. N. R. Lenard and H. R. Berthoud, “Central and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes,” Obesity 16 (Suppl 3, 2008): S11–S22.

8. W. A. Banks, A. J. Kastin, W. Huang, J. B. Jaspan, and L. M. Maness, “Leptin Enters the Brain by a Saturable System Independent of Insulin,” Peptides 17, no. 2 (1996): 305–311.

9. N. Satoh, Y. Ogawa, G. Katsuura, M. Hayase, T. Tsuji, K. Imagawa, Y. Yoshimasa, S. Nishi, K. Hosoda, and K. Nakao, “The Arcuate Nucleus as a Primary Site of Satiety Effect of Leptin in Rats,” Neuroscience Letters 224, no. 3 (1997): 149–152.

10. S. Pinto, A. G. Roseberry, H. Liu, S. Diano, M. Shanabrough, X. Cai, J. M. Friedman, and T. L. Horvath, “Rapid Rewiring of Arcuate Nucleus Feeding Circuits by Leptin,” Science 304 (2004): 110–115.

11. P. J. Scarpace and Y. Zhang, “Leptin Resistance: A Predisposing Factor for Diet-Induced Obesity,” American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 296, no. 3 (2009): R493–R500.

12. M. Shintani, Y. Ogawa, K. Ebihara, M. Aizawa-Abe, F. Miyanaga, K. Takaya, T. Hayashi, G. Inoue, K. Hosoda, M. Kojima, K. Kangawa, and K. Nakao, “Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway,” Diabetes 50, no. 2 (2001): 227–232.

13. C. B. Lawrence, A. C. Snape, F. M. Baudoin, and S. M. Luckman, “Acute Central Ghrelin and GH Secretagogues Induce Feeding and Activate Brain Appetite Centers,” Endocrinology 143, no. 1 (2002): 155–162.

14. L. Wang, D. H. Saint-Pierre, and Y. Taché, “Peripheral Ghrelin Selectively Increases Fos Expression in Neuropeptide Y–Synthesizing Neurons in Mouse Hypothalamic Arcuate Nucleus,” Neuroscience Letters 325, no. 1 (2002): 47–51.

15. Z. B. Andrews, Z. W. Liu, N. Walllingford, D. M. Erion, E. Borok, J. M. Friedman, M. H. Tschöp, M. Shanabrough, G. Cline, G. I. Shulman, A. Coppola, X. B. Gao, T. L. Horvath, and S. Diano, “UCP2 Mediates Ghrelin’s Action on NPY/AgRP Neurons by Lowering Free Radicals,” Nature 454, no. 7206 (2008): 846–851.

16. C. Davis and S. Kaptein, “Anorexia Nervosa with Excessive Exercise: A Phenotype with Close Links to Obsessive-Compulsive Disorder,” Psychiatry Research 142, nos. 2–3 (2006): 209–217.



About Cerebrum

 
Bill Glovin, editor
Carolyn Asbury, Ph.D., consultant

Scientific Advisory Board
Joseph T. Coyle, M.D., Harvard Medical School
Kay Redfield Jamison, Ph.D., The Johns Hopkins University School of Medicine
Pierre J. Magistretti, M.D., Ph.D., University of Lausanne Medical School and Hospital
Robert Malenka, M.D., Ph.D., Stanford University School of Medicine
Bruce S. McEwen, Ph.D., The Rockefeller University
Donald Price, M.D., The Johns Hopkins University School of Medicine

Do you have a comment or question about something you've read in CerebrumContact Cerebrum Now.